Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 122

1.

Prognostic significance of the controlling nutritional status (CONUT) score in advanced urothelial carcinoma patients.

Suzuki H, Ito M, Takemura K, Nakanishi Y, Kataoka M, Sakamoto K, Tobisu KI, Koga F.

Urol Oncol. 2019 Dec 18. pii: S1078-1439(19)30438-7. doi: 10.1016/j.urolonc.2019.10.014. [Epub ahead of print]

PMID:
31864938
2.
3.

Serum γ-Glutamyltransferase as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide.

Takemura K, Ito M, Nakanishi Y, Kataoka M, Sakamoto K, Suzuki H, Tobisu KI, Koga F.

Anticancer Res. 2019 Oct;39(10):5773-5780. doi: 10.21873/anticanres.13780.

PMID:
31570481
4.

What are roles of multiparametric magnetic resonance imaging prior to transurethral resection of bladder tumor?

Koga F.

Transl Androl Urol. 2019 Aug;8(4):290-291. doi: 10.21037/tau.2019.07.21. No abstract available.

5.

Impact of fluorodeoxyglucose uptake on positron emission tomography/computed tomography on chemosensitivity and survival in patients with metastatic urothelial carcinoma.

Kobayashi M, Tanaka H, Tateishi U, Numao N, Yonese J, Ito M, Koga F, Fukushima H, Uehara S, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y.

Int J Urol. 2019 Aug;26(8):820-826. doi: 10.1111/iju.14022. Epub 2019 May 28.

PMID:
31140215
6.

Who Can Avoid Systematic Biopsy Without Missing Clinically Significant Prostate Cancer in Men Who Undergo Magnetic Resonance Imaging-Targeted Biopsy?

Nakanishi Y, Ito M, Fukushima H, Yokoyama M, Kataoka M, Ikuta S, Sakamoto K, Takemura K, Suzuki H, Tobisu KI, Koga F.

Clin Genitourin Cancer. 2019 Jun;17(3):e664-e671. doi: 10.1016/j.clgc.2019.03.011. Epub 2019 Mar 27.

PMID:
31003892
7.

Heat shock factor 1 (HSF1)-targeted anticancer therapeutics: overview of current preclinical progress.

Kijima T, Prince T, Neckers L, Koga F, Fujii Y.

Expert Opin Ther Targets. 2019 May;23(5):369-377. doi: 10.1080/14728222.2019.1602119. Epub 2019 Apr 7.

PMID:
30931649
8.

Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients.

Kijima T, Tanaka H, Koga F, Masuda H, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y.

BJU Int. 2019 Aug;124(2):242-250. doi: 10.1111/bju.14736. Epub 2019 Apr 3.

PMID:
30811784
9.

Multifocal Synchronous Upper Urinary Tract Carcinosarcoma (Sarcomatoid Carcinoma) With Rhabdomyoblastic Differentiation.

Takemura K, Motoi T, Tonooka A, Funata N, Nakanishi Y, Kataoka M, Ito M, Sakamoto K, Suzuki H, Tobisu KI, Koga F.

Int J Surg Pathol. 2019 Aug;27(5):547-552. doi: 10.1177/1066896919828111. Epub 2019 Feb 15.

PMID:
30767589
10.

Metabolic and Molecular Basis of Sarcopenia: Implications in the Management of Urothelial Carcinoma.

Fukushima H, Fujii Y, Koga F.

Int J Mol Sci. 2019 Feb 11;20(3). pii: E760. doi: 10.3390/ijms20030760. Review.

11.

Prognostic significance of serum γ-glutamyltransferase in patients with advanced urothelial carcinoma.

Takemura K, Fukushima H, Ito M, Kataoka M, Nakanishi Y, Sakamoto K, Suzuki H, Tobisu KI, Koga F.

Urol Oncol. 2019 Feb;37(2):108-115. doi: 10.1016/j.urolonc.2018.11.002. Epub 2018 Nov 24.

PMID:
30478012
12.

A Case of Renal Pelvic Cancer Complicated by Horseshoe Kidney Treated with RoboSurgeon Gasless Single-Port Retroperitoneoscopic Nephroureterectomy.

Suzuki H, Takemura K, Sakamoto K, Kataoka M, Ito M, Nakanishi Y, Tobisu KI, Koga F.

Case Rep Urol. 2018 Sep 18;2018:3231480. doi: 10.1155/2018/3231480. eCollection 2018.

13.

Impact of Sarcopenia as a Prognostic Biomarker of Bladder Cancer.

Fukushima H, Takemura K, Suzuki H, Koga F.

Int J Mol Sci. 2018 Oct 1;19(10). pii: E2999. doi: 10.3390/ijms19102999. Review.

14.

Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.

Koga F, Takemura K, Fukushima H.

Int J Mol Sci. 2018 Sep 15;19(9). pii: E2777. doi: 10.3390/ijms19092777. Review.

15.

Impact of Immunohistochemistry-Based Subtypes in Muscle-Invasive Bladder Cancer on Response to Chemoradiation Therapy.

Tanaka H, Yoshida S, Koga F, Toda K, Yoshimura R, Nakajima Y, Sugawara E, Akashi T, Waseda Y, Inoue M, Kijima T, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Kihara K, Fujii Y.

Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1408-1416. doi: 10.1016/j.ijrobp.2018.06.030. Epub 2018 Jun 28.

PMID:
29960059
16.

[PRIMARY MALIGNANT MELANOMA OF THE FEMALE URETHRA: A CASE REPORT].

Suzuki H, Nakanishi Y, Yoshino K, Kataoka M, Fukushima H, Tobisu K, Koga F.

Nihon Hinyokika Gakkai Zasshi. 2018;109(2):111-115. doi: 10.5980/jpnjurol.109.111. Japanese.

17.

Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer.

Matsumoto A, Nakagawa T, Kanatani A, Ikeda M, Kawai T, Miyakawa J, Taguchi S, Naito A, Otsuka M, Nakanishi Y, Suzuki M, Koga F, Nagase Y, Kondo Y, Okaneya T, Tanaka Y, Miyazaki H, Fujimura T, Fukuhara H, Kume H, Igawa Y, Homma Y.

World J Urol. 2018 Feb;36(2):249-256. doi: 10.1007/s00345-017-2141-2. Epub 2017 Nov 28.

PMID:
29185045
18.

Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.

Fukushima H, Kataoka M, Nakanishi Y, Sakamoto K, Takemura K, Suzuki H, Ito M, Tobisu KI, Fujii Y, Koga F.

Urol Oncol. 2018 Apr;36(4):156.e9-156.e16. doi: 10.1016/j.urolonc.2017.09.016. Epub 2017 Oct 17.

PMID:
29051030
19.

Ureteral Involvement Is Associated with Poor Prognosis in Upper Urinary Tract Urothelial Carcinoma Patients Treated by Nephroureterectomy: A Multicenter Database Study.

Waseda Y, Saito K, Ishioka J, Matsuoka Y, Numao N, Fujii Y, Sakai Y, Koga F, Okuno T, Arisawa C, Kamata S, Nagahama K, Masuda H, Yonese J, Kageyama Y, Noro A, Tsujii T, Morimoto S, Gotoh S, Kihara K.

Eur Urol Focus. 2016 Aug;2(3):296-302. doi: 10.1016/j.euf.2015.10.008. Epub 2015 Nov 26.

PMID:
28723376
20.

Standardization of the apparent diffusion coefficient value of bladder cancer across different centers: Applicability in predicting aggressive pathologic phenotypes.

Nishizawa T, Yoshida S, Koga F, Tanaka H, Kaga M, Watanabe K, Fukushima H, Nakanishi Y, Yokoyama M, Ishioka J, Matsuoka Y, Saito K, Fujii Y, Kihara K.

Clin Imaging. 2017 Jul - Aug;44:121-126. doi: 10.1016/j.clinimag.2017.05.004. Epub 2017 May 5.

PMID:
28505504

Supplemental Content

Loading ...
Support Center